Recent Updates
Recently added Catalysts
LAB Positive Sentiment

Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025

Key Takeaway: Standard BioTools Inc. will announce its second quarter 2025 financial results on August 11, 2025. A conference call will be held at 4:30 p.m. ET to discuss these results and the company's operational progress. The call will be accessible via phone and online webcast, with an archive available afterward.
Price reaction · baseline $1.23 (2025-07-18 close) · hit pre-market · clean, no other LAB news in the window
day 0 close · peak
+2.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Standard BioTools is reporting its financial results, indicating transparency.
  • The company is hosting a conference call to discuss operational progress.
  • Standard BioTools is recognized for its innovative technologies in biomedical research.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~27 mo
Minimal dilution risk
Lead asset
Spanish Black Radish product
Phase 1 · Healthy

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report second quarter 2025 financial results on Monday, August 11, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress.
Individuals can access the conference call by dialing:
US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297
Live audio of the webcast will be available online on the Investor Relations page of the Company’s website atEvents & Presentations. The webcast will be archived and available on Standard BioTools™ Investor Relations page atinvestors.standardbio.com.

About Standard BioTools Inc.

Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop better medicines faster. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more atstandardbio.comor connect with us on X, Facebook®, LinkedIn, and YouTube™.
Limited Use Label License and other terms may apply:standardbio.com/legal/salesterms.Patent and License Information:standardbio.com/legal/notices.©2025 Standard BioTools Inc. All rights reserved.

Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.

Investor Contact:Marissa Bychir@standardbio.com

Frequently Asked Questions

When will Standard BioTools report its Q2 2025 results?

Standard BioTools will report its Q2 2025 financial results on August 11, 2025.

What time is the earnings conference call?

The earnings conference call is scheduled for 4:30 p.m. ET on August 11, 2025.

How can I access the conference call?

The conference call can be accessed by dialing specific numbers for US and international callers.

Where can I find the webcast of the earnings call?

The webcast will be available on the Investor Relations page of Standard BioTools' website.

Last updated: Jul 21, 2025